Maharashtra's drug regulator has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carrying and Forwarding facility at Wadki in Pune. The Maharashtra Food and Drug Administration said on 28 August 2026 that the cancellation took effect from 27 August, after an inspection of the company's main warehouse in the district, according to The Hindu.

The case matters beyond one warehouse. It shows how a single line of packaging text on a prescription-only drug can trigger a seizure, a statewide recall order and, eventually, a licence cancellation, exposing how tightly Indian regulators now police the line between drug information and drug advertising.

What triggered the Cipla Pharma cancellation

The trouble began with Reactin Plus Tablets, a Schedule H medicine that requires a doctor's prescription. Maharashtra FDA found the packaging described the drug as an analgesic and antipyretic, or in some accounts an analgesic and anti-inflammatory, an unauthorised promotional claim that regulators say violates the Drugs and Cosmetics Act, 1940, per The Economic Times.

During a June 2026 raid on the same godown, officials seized Reactin Plus stock worth roughly Rs 11.19 lakh. Schedule H drugs cannot be advertised directly to the public under section 74(p) of the Act, officials told The Times of India. That June crackdown, reported by PTI, seized over Rs 24 lakh worth of medicines across Pune and Kolhapur.

"During the inspection, it was observed that the packaging of Reactin Plus Tablets, a prescription medicine falling under Schedule H, contained promotional advertising related to the use of the medicine. Such advertising was found to be inconsistent with the provisions of the Drugs and Cosmetics Rules, 1945," the FDA said in its June statement, per PTI.

A recall that stayed incomplete

After the June seizure, Maharashtra FDA ordered Cipla Pharma & Life Sciences and manufacturer Cipla HSN International to recall the misbranded tablets from every point in the supply chain: C&F agents, stockists, distributors, wholesalers, retailers and e-commerce platforms across the state.

The follow-up inspection found the job unfinished. FDA's detailed findings cited medicines stored directly on the floor, poor pallet and rack arrangements, weak tracking of expired stock, mismatches between physical inventory and computer records, and incomplete compliance with the Reactin Plus recall itself, according to The Hindu. It is the mix of an unresolved recall and basic warehouse discipline gaps that pushed the case from a show-cause notice to a full licence cancellation, per India Today.

The concern isn't abstract. A Times of India report quoted a Maharashtra FDA joint commissioner (drugs) warning that promotional wording on a prescription-only drug can nudge people toward self-medication, turning a labelling error into a public health risk.

Cipla pushes back

Cipla Pharma has contested the order, calling the matter sub judice. "We would, however, like to clarify that the order does not allege any concerns relating to the safety, quality, or efficacy of our products, nor does it involve or indicate any patient safety issue," a company spokesperson said, per India Today. The company has also told The New Indian Express that the cancellation does not touch product safety, framing it as a compliance dispute rather than a quality failure.

Part of a wider FDA drive

The Cipla Pharma order sits inside a broader enforcement push led by Maharashtra FDA commissioner Tukaram Mundhe, who has said the manufacture, distribution or sale of illegal or improperly promoted medicines will not be tolerated and that action will continue against entities that "play with people's lives," per PTI. Maharashtra's regulators have also moved against other retail and food-linked platforms this year, including the licence suspensions of BigBasket, Instamart and Amazon over Datura listings in Karnataka, part of a pattern of state regulators tightening scrutiny of what reaches consumers.

Investors are already watching Cipla Ltd regulatory record closely on other fronts, including USFDA observations at a separate facility, adding to a sense that compliance issues across the company's manufacturing and distribution network are drawing more attention than before.

[youtube:20]

What happens next

Cipla Ltd's challenge to the cancellation is pending, and the company maintains no product safety issue exists. Until a court rules, the Wadki C&F unit's drug sale licences stay cancelled, and Maharashtra FDA has signalled that storage, record-keeping and recall follow-through will stay under watch across the state's pharma distribution network.